Skip to main content

Table 2 Patient data of FDG and FMISO PET (increase of FMISO uptake; increase of mean SUV of FDG uptake)

From: [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study

Pat.

FMISO

FDG

 

SUV mean before/after Cht.

SUV max. before/after Cht.

Tu./Musc. before/after Cht.

SUV mean before/after Cht.

SUV max before/after Cht.

1

1.90

1.40

2.12

1.83

1.12

1.04

9.70

7.70

12.32

8.16

2

2.20

1.40

2.48

1.63

1.45

1.26

17.10

8.10

20.19

9.69

3

1.90

1.90

2.57

2.43

1.54

1.36

14.10

7.10

16.28

7.96

4

3.70

2.20

4.59

2.43

5.85

1.51

14.00

8.30

19.02

9.40

5

1.60

1.40

1.76

1.65

1.25

1.10

8.50

8.90

10.80

10.18

6

2.20

2.40

2.58

2.71

1.10

1.18

12.00

11.40

14.90

13.68

7a

2.60

2.00

3.02

2.28

1.86

1.75

8.60

10.60

11.85

11.99

7b

2.60

2.00

3.02

2.34

1.86

1.52

8.60

5.10

11.85

7.15

8

2.10

1.80

2.79

2.37

1.89

1.48

1.60

9.70

1.91

14.50

Mean

2.31

1.83

2.77

2.19

1.99

1.36

10.47

8.54

13.23

10.30

SD

0.20

0.12

0.27

0.13

0.49

0.08

1.50

0.63

1.80

0.86

  1. SUV = standard uptake value; Tu./Musc. = tumour to muscle ratio; Cht. = chemotherapy